Arrhythmogenic mechanisms of non-sedating antihistamines

Clinical and Experimental Allergy, Supplement

Volumn 29, Issue 3, 1999, Pages 174-181

  Yap, Y G ^a,b   Camm, A J ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Arrhythmogenic mechanisms; HERG gene; Non sedating; Torsades de pointes

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTIMALARIAL AGENT; APRINDINE; ASTEMIZOLE; BRETYLIUM; CALCIUM CHANNEL BLOCKING AGENT; CHLORPROMAZINE; DISOPYRAMIDE; ENCAINIDE; FLECAINIDE; HALOPERIDOL; HISTAMINE H1 RECEPTOR ANTAGONIST; IMIDAZOLE DERIVATIVE; LITHIUM; MACROLIDE; MEXILETINE; PHENOTHIAZINE DERIVATIVE; PIMOZIDE; POTASSIUM CHANNEL; PRENYLAMINE; PROCAINAMIDE; QUINIDINE; SEMATILIDE; SEROTONIN AGONIST; SOTALOL; TERFENADINE; TERODILINE; UNINDEXED DRUG;

ALLERGY; ARRHYTHMOGENESIS; CARDIOTOXICITY; CARDIOVASCULAR EFFECT; DRUG MECHANISM; DRUG OVERDOSE; HIGH RISK PATIENT; HUMAN; PRIORITY JOURNAL; QT INTERVAL; REVIEW; RISK FACTOR; TORSADE DES POINTES;

EID: 0032793982     PISSN: 09602178     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.1999.0290s3174.x     Document Type: Review

References (47)

1. Woosley RL. Cardiac actions of antihistamines. Ann Rev Pharmacol Toxicol 1996; 36:233-52.
2. Monahan BP, Ferguson CL, Killeavy ES, et al. Torsades de pointes occuring in association with terfenadine use. J Am Med Assoc 1990; 264:2788-90.
3. Zimmerman M, Duruz H, Guinand O, et al. Torsades de pointes after treatment with terfenadine and ketoconazole. Eur Heart J 1992; 13:1002-3.
4. Woosley RL, Chen Y, Freiman JP, Gilles RA. Mechanism of the cardiotoxic actions terfenadine. J Am Med Assoc 1993; 269:1532-6.
5. Snook J, Coothman-Burrell D, Watkins J, Colin-Jones D. Torsades de pointes ventricular tachycardia associated with astemizole overdose. Br J Clin Prac 1988; 42:257-9.
6. Zechnich AD, Hedges JR, Eiselt-Proteau D, Haxby D. Possible interactions with terfenadine or astemizole. West J Med 1994; 160:321-5.
7. Nightingale SL. Warnings issued on nonsedating antihistamines terfenadine and astemizole.
8. Rankin AC. Non-sedating antihistamines and cardiac arrhythmia. Lancet 1997; 349:1115.
9. Zhang M-Q. Chemistry underlying the cardiotoxicity of antihistamiens. Curr Med Chem 1997; 4:171-84.
10. Colatsky TJ. Potassium Channel Modulators, Pharmacological, Molecular and Clinical Aspects. A. H. Weston, T. C. Hamilton, eds. Oxford: Blackwell Scientific Publications, 1992; 304-40.
11. Kawano S, Hiraoka M. Transient outward currents and action potential alternations in rabbit ventricular myocytes. J Mol Cell Cardiol 1991; 23:681-93.
12. Sanguinetti MC, Jurkiewicz NK. Two components of cardiac delayed rectifier current: differential sensitivity to block by class III antiarrhythmic agent. J Gen Physiol 1990; 96:195-215.
13. Sakmann B, Trube G. Conductance properties of single inwardly rectifying potassium channels in ventricular cells from guinea pig heart. J Physiol 1984; 347:641-57.
14. Berul CI, Morad M. regulation of potassium channels by nonsedating antihistamines. Circulation 1995; 91:2220-5.
15. 1-antihistamines: a roundtable discussion. Kenilworth, USA: Schering-Plough Pharmaceutical, 1996:22-31.
16. Ko CM, Ducic I, Fan J, et al. Suppression of mammalian K channel family by ebastine. J Pharmacol Exp Ther 1997; 281:233-44.
17. Monsuez J-J. Cardiac potassium currents and channels. Part II. Implications for clinical practice and therapy. Int J Cardiol 1997; 62:1-12.
18. Noble D. The surprising heart: a review of recent progress in cardiac electrophysiology. J Physiol 1984; 353:1-50.
19. Sicouri S, Antzelevitch C. S subpopulation of cells with unique electrophysiological properties in the deep subepicardium of the canine ventricle. The M cell. Circ Res 1991; 68:1729-41.
20. Antzelevitch C, Davidenko JM, Sicouri S, et al. Quinidine-induced early afterdepolarisation and triggered activity. J Electrophysiol 1989; 3:323-38.
21. Carmeliet E. Voltage- and time-dependent block of the delayed K current in cardiac myocytes by dofetilide. J Pharmacol Exp Ther 1992; 262:809-17.
22. Haverkamp W, et al. eds. Cardiac Electrophysiology: From Cell to Bedside. 2nd edn, Philadelphia: W.B. Saunders, 1995:885-9.
23. Hu JTY, Wyse DG, Gillis AM, et al. Precordial QT interval dispersion as a marker of torsades de pointes. Circulation 1992; 86:1376-82.
24. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995; 81:299-307.
25. Roy ML, Dumaine R, Brown AM. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 1996; 94:817-23.
26. Salata JJ, Jurkeiwicz NK, Wallace AA, et al. Cardiac electrophysiological actions of the histamine H1-receptor antogonists astemizole and terfenadine compared with chlopheniramine and pyrilamine. Circ Res 1995; 76:110-9.
27. Pinney SP, Koller BS, Franz MR, Woosley RL. Terfenadine increases the QT interval in isolated guinea pig heart. J Cardiovasc Pharmacol 1995; 25:30-4.
28. Woosley RL, Chen Y. Synergistic effects of ketoconazole and terfenadine on cardiac repolarisation. Clin Res 1994; 42:329A (Abstract).
29. Honig PK, Woosley RL, Zamani K, et al. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine and concomitant administration of erythromycin. Clin Pharmacol Ther 1992; 52:231-8.
30. Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. J Am Med Assoc 1993; 269:1513-8.
31. Honig PK, Wortham DC, Hull R, et al. Itraconazole affects single-dose terfenadine pahemacokinetics and cardiac repolarisation pharmacodynamics. J Clin Pharmacol 1993; 33:1201-6.
32. Honig PK, Wortham DC, Zamani K, et al. The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans. Clin Pharmacol Ther 1993; 53:630-6.
33. Lindquist M, Edwards IR. Dangers of non-sedating antihistamines. Lancet 1997; 350:69-70 (letter).
34. Brannan M, Reidenberg P, Radwanski E, et al. Loratidine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations. Clin Pharmacol Ther 1995; 58:269-78.
35. Hey J, del Prado M, Egan RW, et al. Loratidine produces antihistamine activity without adverse CNS, ECG or cardiovascular effects in guinea pigs. Comparative studies with terfenadine and sedating antihistamines. Int Arch Allergy Immunol 1995; 107:418-9.
36. Sale ME, Barbey JT, Woosley RL, et al. The electrocardiographic effects of cetirizine in normal subjects. Clin Pharmacol Ther 1994; 56:295-301.
37. Lindquist M, Edwards IR. Risks of non-sedating antihistamines. Lancet 1997; 349:1322 (letter).
38. Morganroth J. Relationship of QTc prolongation on the electrocardiogram to torsades de pointes: defenitions and mechanisms. Am J Cardiol 1993; 72:10B-13B.
39. Moss AJ. Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. Am J Cardiol 1993; 72:23B-25B.
40. Roden DM, Torsades de Pointes. Clin Cardiol 1993; 16:683-6.
41. Kay GN, Plumb VJ, Arciniegas JG, et al. Torsades de pointes: The long-short initiating sequence and other clinical features: Observations in 32 patients. J Am Coll Cardiol 1983; 2:806-17.
42. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: Implications for patient care. Am Heart J 1986; 111:1088-93.
43. Jackman WM, Friday KJ, Anderson JL, et al. The long QT syndrome: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 1988; 31:115-72.
44. Thomas SHL. Drugs and the QT interval. Adv Drug Reac Bull 1997; 182:691-4.
45. Houltz B, Darpo B, Edvardsson N, et al. Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study. PACE 1998; 21:1044-57.
46. Smith SJ. Cardiovascular toxicity of antihistamines. Otolaryngol Head Neck Surg 1994; 111:348-54.
47. Vukmir RB. Torsades de pointes: a review. Am J Emerg Med 1991; 9:250-5.